FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1497100549> ?p ?o ?g. }

• W1497100549 endingPage "84" @default.
• W1497100549 startingPage "77" @default.
• W1497100549 abstract "The deficit of 25-hydroxyvitamin D (25OHD) associated with secondary hyperparathyroidism (SHPT) is a frequent finding in chronic kidney disease (CKD) patients on haemodialysis (HD). These events are associated with increased morbidity and mortality rates of cardiovascular (CV) origin. Adequate 25OHD serum levels as well as the use of selective vitamin D receptor activators (VDRA) have been shown to have beneficial and independent effects on bone mineral metabolism and cardiovascular risk. Currently, there is still controversy regarding the type of supplementation needed by CKD patients on HD.The aim of our study was to evaluate whether there is a benefit of combination therapy with 25OHD, calcifediol and a VDRA, oral paricalcitol, on bone-mineral metabolism and inflammatory markers, compared to single treatment with each of these in a group of patients on HD.We performed a prospective study of 6 months, involving 26 patients in our HD unit. We randomised patients into two groups: group 1 (G1) received oral paricalcitol treatment at doses of 1 mcg/day. Group 2 (G2) was treated with 1 ampoule calcifediol/wk (0.266 mg/wk=16 000U) orally. After 3 months of treatment, calcifediol and paricalcitol were added to the G1 and G2 respectively at the same doses, keeping these treatments together for 3 months to complete the 6 months of follow-up. Laboratory tests were performed at months 0, 3 and 6, measuring in all patients serum markers of 25OHD, calcium (Ca), phosphorus (P) and PTH. Bone turnover markers measured were: alkaline phosphatase (AP), aminoterminal propeptide of procollagen type 1 (Pinp1) and carboxyl-terminal telopeptide of type I collagen (CrossLaps), and inflammatory markers: IL-8. We also collected data on levels of insulin, glucose, haemoglobin, erythropoiesis-stimulating agents (ESAs) and rates of resistance to EPO and HOMA (homeostasis model assessment).We detected a deficit of 25-hydroxyvitamin D in all patients studied, with a mean of 13.67 ± 4.81 ng/ml. Supplementation with oral calcifediol significantly corrects this deficit without evidence of toxicity (35.36 ± 33.68 ng/ml in G1 at 6 months and 59.21 ± 26.50 ng/ml in G2 at 3 months). Paricalcitol treatment significantly reduces PTH levels in G1 at 3 months (P<.039). We also noted a decrease in bone marker Pinp1 with paricalcitol, pointing to a possible direct effect on bone cells (P<.001). Both treatment with paricalcitol and with calcifediol produced a significant decrease in levels of IL-8 (P<.001), a known inflammatory marker, drawing attention to a trend towards better response to erythropoiesis-stimulating agents (ESAs), possibly related to the decrease in inflammation. The HOMA index did not change significantly.Based on our results, we cannot conclude that the association of calcifediol and paricalcitol produces advantages over the effect of each drug separately. In addition, Paricalcitol by itself appears to have a direct effect on cellular bone remodelling." @default.
• W1497100549 created "2016-06-24" @default.
• W1497100549 creator A5009492539 @default.
• W1497100549 creator A5016761924 @default.
• W1497100549 creator A5049549432 @default.
• W1497100549 creator A5051418515 @default.
• W1497100549 creator A5058418542 @default.
• W1497100549 creator A5060901092 @default.
• W1497100549 creator A5068648020 @default.
• W1497100549 creator A5080881193 @default.
• W1497100549 creator A5091714514 @default.
• W1497100549 date "2013-01-18" @default.
• W1497100549 modified "2023-10-18" @default.
• W1497100549 title "Double treatment with paricalcitol-associated calcifediol and cardiovascular risk biomarkers in haemodialysis." @default.
• W1497100549 cites W1533415810 @default.
• W1497100549 cites W1583951223 @default.
• W1497100549 cites W1970223241 @default.
• W1497100549 cites W1972317723 @default.
• W1497100549 cites W1982299887 @default.
• W1497100549 cites W2009353805 @default.
• W1497100549 cites W2017335874 @default.
• W1497100549 cites W2036132254 @default.
• W1497100549 cites W2074826032 @default.
• W1497100549 cites W2080387599 @default.
• W1497100549 cites W2089612021 @default.
• W1497100549 cites W2110238698 @default.
• W1497100549 cites W2133122323 @default.
• W1497100549 cites W2134876607 @default.
• W1497100549 cites W2151059482 @default.
• W1497100549 cites W2160234571 @default.
• W1497100549 cites W2162129240 @default.
• W1497100549 cites W2555924635 @default.
• W1497100549 doi "https://doi.org/10.3265/nefrologia.pre2012.sep.11533" @default.
• W1497100549 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23364629" @default.
• W1497100549 hasPublicationYear "2013" @default.
• W1497100549 type Work @default.
• W1497100549 sameAs 1497100549 @default.
• W1497100549 citedByCount "2" @default.
• W1497100549 countsByYear W14971005492012 @default.
• W1497100549 countsByYear W14971005492015 @default.
• W1497100549 crossrefType "journal-article" @default.
• W1497100549 hasAuthorship W1497100549A5009492539 @default.
• W1497100549 hasAuthorship W1497100549A5016761924 @default.
• W1497100549 hasAuthorship W1497100549A5049549432 @default.
• W1497100549 hasAuthorship W1497100549A5051418515 @default.
• W1497100549 hasAuthorship W1497100549A5058418542 @default.
• W1497100549 hasAuthorship W1497100549A5060901092 @default.
• W1497100549 hasAuthorship W1497100549A5068648020 @default.
• W1497100549 hasAuthorship W1497100549A5080881193 @default.
• W1497100549 hasAuthorship W1497100549A5091714514 @default.
• W1497100549 hasConcept C124490489 @default.
• W1497100549 hasConcept C126322002 @default.
• W1497100549 hasConcept C126894567 @default.
• W1497100549 hasConcept C134018914 @default.
• W1497100549 hasConcept C170033053 @default.
• W1497100549 hasConcept C2775945674 @default.
• W1497100549 hasConcept C2776169692 @default.
• W1497100549 hasConcept C2776541429 @default.
• W1497100549 hasConcept C2776886416 @default.
• W1497100549 hasConcept C2776941976 @default.
• W1497100549 hasConcept C2778653478 @default.
• W1497100549 hasConcept C2778838027 @default.
• W1497100549 hasConcept C2779126354 @default.
• W1497100549 hasConcept C2779524405 @default.
• W1497100549 hasConcept C2779740938 @default.
• W1497100549 hasConcept C2781208988 @default.
• W1497100549 hasConcept C519063684 @default.
• W1497100549 hasConcept C71924100 @default.
• W1497100549 hasConcept C90924648 @default.
• W1497100549 hasConceptScore W1497100549C124490489 @default.
• W1497100549 hasConceptScore W1497100549C126322002 @default.
• W1497100549 hasConceptScore W1497100549C126894567 @default.
• W1497100549 hasConceptScore W1497100549C134018914 @default.
• W1497100549 hasConceptScore W1497100549C170033053 @default.
• W1497100549 hasConceptScore W1497100549C2775945674 @default.
• W1497100549 hasConceptScore W1497100549C2776169692 @default.
• W1497100549 hasConceptScore W1497100549C2776541429 @default.
• W1497100549 hasConceptScore W1497100549C2776886416 @default.
• W1497100549 hasConceptScore W1497100549C2776941976 @default.
• W1497100549 hasConceptScore W1497100549C2778653478 @default.
• W1497100549 hasConceptScore W1497100549C2778838027 @default.
• W1497100549 hasConceptScore W1497100549C2779126354 @default.
• W1497100549 hasConceptScore W1497100549C2779524405 @default.
• W1497100549 hasConceptScore W1497100549C2779740938 @default.
• W1497100549 hasConceptScore W1497100549C2781208988 @default.
• W1497100549 hasConceptScore W1497100549C519063684 @default.
• W1497100549 hasConceptScore W1497100549C71924100 @default.
• W1497100549 hasConceptScore W1497100549C90924648 @default.
• W1497100549 hasIssue "1" @default.
• W1497100549 hasLocation W14971005491 @default.
• W1497100549 hasOpenAccess W1497100549 @default.
• W1497100549 hasPrimaryLocation W14971005491 @default.
• W1497100549 hasRelatedWork W2036918810 @default.
• W1497100549 hasRelatedWork W2097260998 @default.
• W1497100549 hasRelatedWork W2147487489 @default.
• W1497100549 hasRelatedWork W2255402789 @default.
• W1497100549 hasRelatedWork W2400300924 @default.
• W1497100549 hasRelatedWork W2750365008 @default.

• next